A5053191395- Advances in Oncology and Radiotherapy
- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Radiation Dose and Imaging
- Health Systems, Economic Evaluations, Quality of Life
- Global Cancer Incidence and Screening
- Radiomics and Machine Learning in Medical Imaging
- Urinary and Genital Oncology Studies
- Bladder and Urothelial Cancer Treatments
- Diversity and Career in Medicine
- COVID-19 and healthcare impacts
- Cancer survivorship and care
- Glioma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Statistical Methods in Clinical Trials
- Lung Cancer Treatments and Mutations
- Healthcare Policy and Management
- Radiation Therapy and Dosimetry
- Radiology practices and education
- Breast Cancer Treatment Studies
- Telemedicine and Telehealth Implementation
- Palliative Care and End-of-Life Issues
- Pharmaceutical Economics and Policy
Flatiron Health (United States)
2021-2025
Wake Forest University
2022-2025
Artistic Realization Technologies
2024-2025
University of North Carolina at Chapel Hill
2012-2023
Forest Institute
2023
Atrium Health Wake Forest Baptist
2022
Dana-Farber Brigham Cancer Center
2017-2021
Brigham and Women's Hospital
2017-2021
Dana-Farber Cancer Institute
2017-2021
Harvard University
2017-2021
Importance There is increasing recognition from regulatory agencies that racial and ethnic representation in clinical trials inadequate linked to health inequities. The extent of inequities trial participation unclear because prior studies have synthesized enrollment data published trials, which often do not report participant race ethnicity. Objective To evaluate oncology a contemporary cohort patients with cancer before during the COVID-19 pandemic. Design, Setting, Participants This study...
PURPOSE The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histopathology–based multimodal artificial intelligence (MMAI) algorithm estimate clinical in SPARTAN. METHODS Patients available hematoxylin and eosin-stained slides from primary tumor were included. Histopathology digitized. MMAI scores ranging 0 1...
Routine cancer screening has unproven net benefit for patients with limited life expectancy.To examine the patterns of prostate, breast, cervical, and colorectal in United States individuals different expectancies.Data from population-based National Health Interview Survey (NHIS) 2000 through 2010 were used included 27 404 participants aged 65 years or older. Using a validated mortality index specific NHIS, grouped into those low (<25%), intermediate (25%-49%), high (50%-74%), very (≥75%)...
Telemedicine for Cancer Care in the Time of COVID-19 On March 30, 2020, US Centers Medicare & Medicaid Services (CMS) released an interim final rule that capped off a dizzying month temporarily loosening regulations to give health care professionals maximum flexibility responding coronavirus disease 2019 (COVID-19) pandemic. 1A primary goal this regulatory flexibility, enabled by President's declaration national emergency and Secretary Department Health Human (HHS) public emergency, is...
<h3>Importance</h3> Women are underrepresented in medical leadership positions; however, representation of women among academic oncology is unknown. <h3>Objectives</h3> To evaluate overall and positions (MO), radiation (RO), surgical (SO) programs to examine the association with faculty per program. <h3>Design, Setting, Participants</h3> In this cross-sectional study, MO, RO, SO training program websites were queried from October 2018 through June 2019. All 265 273 accredited (97.1%)...
Prostate cancer is the most common diagnosis in men United States and a leading cause of cancer-related morbidity mortality ([ 1 ][1]). It can exist along wide spectrum aggressiveness severity, from indolent, very-low-risk, localized prostate to life-threatening,
BackgroundCertain populations have been historically underrepresented in clinical trials. Broadening eligibility criteria is one approach to inclusive research and achieving enrollment goals. How broadened trial affect the diversity of eligible participants unknown. MethodsUsing a nationwide electronic health record–derived deidentified database, we identified retrospective cohort patients diagnosed with 22 cancer types between April 1, 2013 December 31, 2022 who received systemic therapy...
BACKGROUND Timely delivery of care has been identified by the Institute Medicine as an indicator for quality health care, and treatment delay is a potentially modifiable obstacle that can contribute to disparities among African American (AA) Caucasian patients in prostate cancer recurrence mortality. Using Surveillance, Epidemiologic End Results (SEER)‐Medicare linked database, we compared time from diagnosis AA patients. METHODS A total 2506 21,454 diagnosed with localized 2004 through 2007...
<h3>Importance</h3> In response to the opioid epidemic, policies aiming reduce prescribing, misuse, and abuse may have unintended consequence of restricting access necessary therapy for cancer-related pain. It is unknown how prescribing patterns changed among generalists oncologists during this era. <h3>Objective</h3> To examine trends in prescription rates Medicare Part D beneficiaries from 2013 2017 generalists. <h3>Design, Setting, Participants</h3> This repeated cross-sectional study...
This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.
Several surrogates for prostate cancer-specific mortality satisfying the Prentice criteria exist, but whether these are all-cause mortality, and how their performance compares, is unknown.To ascertain compare of 4 candidate (prostate-specific antigen [PSA] failure, PSA nadir >0.5 ng/mL, doubling time <9 months, interval to failure <30 months) using proportion treatment-effect metric.For this randomized clinical trial, 206 men with unfavorable-risk cancer who were seen at a Harvard-affiliated...
A January 2019 price transparency mandate by the US Centers for Medicare & Medicaid Services (CMS) allows patients to look up prices of cancer treatment services at hospitals across United States.To investigate value CMS rule in allowing with prostate comparison shop radiation among National Cancer Institute-designated centers.We identified February publicly available price-containing chargemasters centers. We isolated charge per fraction intensity-modulated therapy used standard treatment....